An upcoming ISPOR Webinar will explore the challenges in evaluating rare, pediatric, degenerative diseases by sharing the example of Duchenne Muscular Dystrophy (DMD) as a case study. Experts will dive into the complexities of traditional HTA frameworks and share innovative insights on assessing orphan drugs.
This is a unique opportunity to gain valuable knowledge and join the discussion on shaping the future of Health Technology Assessment (HTA) for rare diseases.
Learning Objectives:
- Explore current challenges with traditional value assessment frameworks, focusing on rare diseases and DMD. Understand the key factors influencing societal willingness and ability to pay for treatments.
- Understand the relevance of caregiver burden and why it should be considered a critical factor in decision-making for new DMD treatments, from both the patient and payer perspectives.
- Learn methods for capturing these factors in the HTA context for DMD, including the impact on caregiver costs and well-being.
Free Registration: Secure your spot now by registering here.
This event is sponsored by Italfarmaco S.p.A.